Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.

Fatima BikhezarRobin M de KruijffAstrid J G M van der MeerGuzman Torrelo VillaSusanne M A van der PolGabriel Becerril AragonAna Gasol GarciaRavi S NarayanHelga E de VriesBen J SlotmanAntonia G DenkovaPeter Sminia

Published in: Journal of neuro-oncology (2019)

MEK162 loaded polymersomes are taken up by multicellular spheroids. The nanocarrier delivered drug reduced spheroid growth and inhibited its molecular target. MEK162 delivered via polymersomes showed interaction with irradiation and TMZ. The polymersomes crossed the in vitro BBB model and therewith offer exciting challenges ahead for delivery of therapeutics agents to brain tumours.

Keyphrases

drug delivery
cancer therapy
pi k akt
drug release
small molecule
blood brain barrier
white matter
radiation induced
emergency department
resting state
multiple sclerosis
cell therapy
radiation therapy
single molecule
drug induced
subarachnoid hemorrhage
wound healing